Ann: PAT-DX1 engineering update, page-102

In addition to its potential as a therapeutic agent in its own right, PAT-DX3 is also currently being
tested as a targeting antibody for antibody drug conjugates (ADCs) to allow the delivery of various
therapeutic payloads. The fact that PAT-DX3 can transit the BBB will be of particular relevance if it can
successfully be conjugated to small molecule drugs.

I believe that this will be included in the next ann. I also believe that the sp has already factored this in. How the good Dr. sells this is very important. If a bit fluffy, the market will react negatively. If spot on and coupled with a peer review...............I expect a spike in sp

The delays have now been cemented into our heads so any deflection away from the cause of delay will not be tolerated. Finalise the delay issues and then ann DX-3 progress and we should be back on the horse again